MARKET

LGVN

LGVN

Longeveron Inc
NASDAQ
0.5819
+0.0105
+1.84%
Opening 15:58 01/06 EST
OPEN
0.5769
PREV CLOSE
0.5714
HIGH
0.5929
LOW
0.5600
VOLUME
244.45K
TURNOVER
--
52 WEEK HIGH
2.240
52 WEEK LOW
0.4920
MARKET CAP
12.41M
P/E (TTM)
-0.4354
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LGVN last week (1229-0102)?
Weekly Report · 1d ago
Weekly Report: what happened at LGVN last week (1222-1226)?
Weekly Report · 12/29/2025 10:05
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
Barchart · 12/29/2025 08:15
Weekly Report: what happened at LGVN last week (1215-1219)?
Weekly Report · 12/22/2025 10:05
Longeveron granted U.S. patent for method of treating female sexual dysfunction
TipRanks · 12/17/2025 14:20
Longeveron Secures USPTO Patent For MSC Therapy Targeting Female Sexual Dysfunction
Benzinga · 12/17/2025 14:17
LONGEVERON GRANTED U.S. PATENT FOR METHOD OF TREATING FEMALE SEXUAL DYSFUNCTION USING ITS PROPRIETARY STEM CELL THERAPY
Reuters · 12/17/2025 14:15
Longeveron Granted U.S. Patent for Stem Cell Therapy to Treat Female Sexual Dysfunction
Reuters · 12/17/2025 14:15
More
About LGVN
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.

Webull offers Longeveron Inc stock information, including NASDAQ: LGVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LGVN stock methods without spending real money on the virtual paper trading platform.